# Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

> **NCT07101159** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Early Breast Cancer
- Adjuvant Therapy
- Hormone Receptor Positive / HER2-negative Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- **DRUG:** Dalpiciclib

## Key facts

- **NCT ID:** NCT07101159
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101159, "Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07101159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*